A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

Shanghai Wanxing Bio-Pharmaceutical

Status and phase

Completed

Phase 1

Conditions

Prophylaxis Against Plasmodium Falciparum Malaria

Treatments

Biological: Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00284973

WanMal002

Details and patient eligibility

About

Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720. This trial is designed to test the safety and immunogenicity of 3 doses and 2 vaccination schedules.

This blood stage candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.

Full description

This is a double blind, randomized, controlled Phase I study of PfCp2.9, an experimental malaria vaccine candidate, adjuvanted with Montanide ISA 720.

The primary objective of this study is to assess the safety and reactogenicity of the vaccine in healthy Chinese adult volunteers.

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy male or female ≥ 18 and ≤ 45 years of age
Agrees not to donate blood during the course of the trial.
Signed written informed consent provided.
Available to participate for the study duration.

Exclusion criteria

History of allergic reactions following any vaccination.
Involvement in drug or other vaccine trial within four weeks prior to the trial.
Acute illness within four weeks prior to the trial.
Presence of fever at the time of vaccination, i.e. body temperature (by axillary) > 37.5 C.
Presence of any chronic illness/disease including diabetes mellitus, tuberculosis, leprosy, epilepsy and hypertension determined by medical history or examination.
Persons on systemic corticosteroids, immunomodulators or anticoagulants within four weeks prior to vaccination.
Persons with a history of allergic manifestations requiring treatment with injectable antihistamines, adrenaline or steroids.
Pregnancy. Women should not be pregnant, lactating, or planning pregnancy throughout the study period. A urinary pregnancy test (immuno-chromatography) will be performed for all women of child-bearing potential at entry and prior to each vaccination. Adequate contraception throughout the study should be used if applicable.
Sexually active woman not using contraceptives.
Current smoker ( ≥ 20 cigarettes/day).
History of malaria: persons with a known history of malaria or with positive markers for antibodies to malaria parasite by IFA and/or ELISA.
History of residing in a malaria endemic region or malaria exposure (travel) within last two years.
Abnormal hematology and clinical chemistry considered to be clinically significant.
Abnormal urine routine test considered to be clinically significant
Persons with positive markers for HBV (HBsAg) and/or HCV (Anti-HCV) infection.